Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Takeda

Status: Completed

Conditions: Hepatocellular Cancer

Treatments: Drug: Cabozantinib

Study type: Observational

Funder types: Industry

Identifiers

NCT05100082

jRCT2031210403 (Registry Identifier)

Cabozantinib-5002

Details and patient eligibility

About

This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with hepatocellular carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 12 months.

Enrollment: 263 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Participants with unresectable hepatocellular carcinoma that has progressed after cancer chemotherapy (Regardless of previous treatment history)

Exclusion criteria

Participants who has a history of hypersensitivity to any component of cabozantinib.

Trial design

263 participants in 1 patient group

Cabozantinib 60 mg

Description:

Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.

Treatment:

Drug: Cabozantinib